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ABSTRACT
Background EML4- ALK is a distinct molecular entity 
that is highly sensitive to ALK tyrosine kinase inhibitors 
(TKIs). Immune checkpoint inhibitors (ICIs) have not proved 
efficacy in ALK- positive non- small cell lung cancer so far. 
In this study, we performed a mouse clinical trial using 
EML4- ALK transgenic mice model to comprehensively 
investigate immunomodulatory effects of ALK TKI and to 
investigate the mechanisms of resistance to ICIs.
Methods EML4- ALK transgenic mice were randomized 
to three treatment arms (arm A: antiprogrammed death 
cell protein-1 (PD-1), arm B: ceritinib, arm C: anti- PD-1 
and ceritinib), and tumor response was evaluated using 
MRI. Progression- free survival and overall survival were 
measured to compare the efficacy. Flow cytometry, 
multispectral imaging, whole exome sequencing and RNA 
sequencing were performed from tumors obtained before 
and after drug resistance.
Results Mouse clinical trial revealed that anti- PD-1 
therapy was ineffective, and the efficacy of ceritinib 
and anti- PD-1 combination was not more effective 
than ceritinib alone in the first line. Dynamic changes 
in immune cells and cytokines were observed following 
each treatment, while changes in T lymphocytes were 
not prominent. A closer look at the tumor immune 
microenvironment before and after ceritinib resistance 
revealed increased regulatory T cells and programmed 
death- ligand 1 (PD- L1)- expressing cells both in the tumor 
and the stroma. Despite the increase of PD- L1 expression, 
these findings were not accompanied by increased effector 
T cells which mediate antitumor immune responses.
Conclusions ALK- positive tumors progressing on ceritinib 
is not immunogenic enough to respond to immune 
checkpoint inhibitors.
BACKGROUND
Molecular profiling of non- small cell lung 
cancer (NSCLC) has led to the discovery of 
a diverse catalog of genetic aberrations that 
drive and sustain tumorigenesis. Of these, 
EML4- ALK rearrangement represents an 
example of a lung oncogenic driver that 
can be therapeutically targeted.1 Numerous 
randomized trials and meta- analyses have 
been conducted to suggest the superiority of 
ALK tyrosine kinase inhibitors (TKIs) over 
cytotoxic chemotherapy in the treatment of 
ALK- rearranged NSCLC. These trials showed 
consistent and significant advantages of ALK 
TKIs in terms of both objective response rate 
(ORR) and progression- free survival (PFS).2–6 
Despite the excellent disease control with 
initial ALK TKI therapy, acquired resistance 
to ALK TKI invariably develops and the 
strategy to overcome resistance remains a key 
challenge.
The recent ‘game- changer’ in the treat-
ment of NSCLC is immune checkpoint 
inhibitors (ICIs). Antiprogrammed death 
cell protein-1 (PD-1) or antiprogrammed 
death- ligand 1 (PD- L1) is able to induce 
durable long- term remissions, with superior 
antitumor efficacy compared with conven-
tional chemotherapy in the frontline setting.7 
However, the majority of clinical trials have 
limited the use of ICIs to patients with EGFR 
mutation or ALK fusion wild type, meaning 
that these oncogene- addicted patients have 
been excluded from the benefit of ICIs. 
There are pieces of evidence that ICIs are less 
efficacious in oncogene- addicted patients. 
In multiple clinical trials and retrospective 
studies, ICIs have shown minimal benefit in 
never- smoking patients.7–9 In the phase II 
ATLANTIC study of durvalumab, no responses 
were observed among 15 patients with ALK- 
positive NSCLC.10 In addition, retrospective 
analysis on the efficacy of ICIs in patients with 
NSCLC with targetable oncogenes (Immuno-
Target) revealed that the ORR of ICIs was 0% 
among ALK- positive patients.11 Several trials 
assessing the combination of ALK TKI with 
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ICIs have also been reported, and the efficacy of ALK 
TKI in combination with ICIs in treatment- naïve patients 
(alectinib and atezolizumab) showed a response rate of 
86%, with median PFS of 21.7 months.12 Considering the 
impressive PFS of 34.8 months obtained with the first- 
line alectinib in the phase III ALEX trial,13 it does not 
seem that combination of alectinib and atezolizumab is 
more advantageous than alectinib monotherapy.14 More 
recently, a combination of ceritinib plus nivolumab was 
shown to have activity, particularly in patients with high 
PD- L1 expression.15 However, significant hepatotoxici-
ties, as represented by increased ALT level, were reported 
in combination trials consisting of ALK TKI and ICIs,15 16 
and the mechanisms underlying hepatotoxicities remain 
unknown.
Several explanations to these poor outcomes of immu-
notherapy in ALK- positive patients with NSCLC have 
been identified, such as the association of ALK rearrange-
ment with low tumor mutation burden (TMB),17 a lack 
of T- cell infiltration9 and variable PD- L1 expression.10 18 
However, the number of patients in these studies was very 
low, and the results were only exploratory.
Before we conclude that a single agent ICI or a combi-
nation of ALK TKI and ICI has no additional value to 
ALK- positive patients, we need further understanding of 
dynamic changes of the tumor- immune microenviron-
ment in response to treatments. In this study, we aimed 
to investigate the comprehensive immunomodulatory 
potential of ALK inhibitor and ICIs in ALK- positive 
NSCLC by using an EML4- ALK transgenic mice model. 
We have previously reported the utility of EML4- ALK 
transgenic mice which recapitulates human ALK- positive 
lung adenocarcinoma.19 Using this model, we conducted 
a mouse clinical trial and compared both efficacy and 
toxicity of different treatment regimens. We also analyzed 
comprehensive immunodynamics and immunoreactivity 
in response to different treatments.
METHODS
EML4-ALK transgenic mice
This study followed worldwide standard animal care condi-
tion via Institutional Animal Care and Use Committee 
(IACUC). The research proposal was approved by 
Yonsei University IACUC (2014-0249). All experimental 
mice were housed in colony cages and maintained on a 
12- light:12 hours dark cycle in the Association for Assess-
ment and Accreditation of Laboratory Animal Care 
International- certified specific pathogen- free facility. 
Conditional EML4- ALK transgenic mice were generated 
as described previously.19 Genotypes of EML4- ALK trans-
genic mice were confirmed by PCR with the following 
three primers: pCB- F: 5’-TGT CTG GAT CCC CAT CAA 
GC-3’, mEML4- intron- F-5’-TTA CCT GCT GTG CCA TCC 
TG-3’, EML4- R_common: 5’-GAA CTC GTG ACT CAA 
GAG CTG-3’. For tumorigenesis, mice were treated with 
tamoxifen twice a week. For tumorigenesis, treatment 
with tamoxifen is needed for activation of Cre- ERT2. 
Tamoxifen (Sigma Chemical, St. Louis, Missouri, USA) 
was given intraperitoneally twice at a 3- day interval, and 
all mice developed lung tumors after 1 week.
Drug treatment in transgenic mice
After tumor formation was confirmed on MRI, mice 
were treated with ALK inhibitor, ceritinib. Ceritinib was 
provided by Novartis Pharmaceuticals, and stored in 
−20ºC until use. Before treatment, ceritinib was diluted 
with 20% PEG400, 3% Tween-80, based on deionized 
water. The diluted ceritinib was homogenized and 
vortexed vigorously, and used within 24 hours. Anti- PD-1 
(BioXcell, West Lebanon, New Hampshire) used was the 
RMP1-14 monoclonal antibody which reacts with mouse 
PD-1 also known as CD279. The drug was stored 4ºC until 
use and diluted with phosphate- buffered saline. Anti- PD-1 
treatment was injected intraperitoneally twice a week at 
the dose of 200 µg per mouse.
MRI and tumor measurement
The optimization of MRI was completed before the begin-
ning of the study. For MRI, the mice were anesthetized 
with isoflurane in 100% oxygen. MRI protocols were opti-
mized for assessing lung parenchyma at 9.4 T (BioSpec 
94/20 USR MRI system (Bruker, Billeria, Massachu-
setts)). All tumors were analyzed on T2- weighted image. 
One week after intraperitoneal treatment with tamoxifen, 
tumor size was measured on MRI. Then TKIs were treated 
after the first MRI. The tumor measurement and response 
evaluation criteria are as following: (1) complete response 
(CR) is defined as complete disappearance of all tumor 
lesions, (2) partial response is defined as >30% shrinkage 
in the sum of tumor diameter from baseline, (3) progres-
sive disease (PD) is defined as the growth of tumor size 
of >20% from the baseline (online supplementary figure 
S1). PFS was defined as the start of the drug treatment 
until the date of disease progression.
Flow cytometry
Tumor tissue was dissociated by collagenase, and then 
isolated cells were preserved in liquid nitrogen tank 
with frozen media until use. Samples were stained with 
the following antibodies: mCD3e (145- 2C11; eBiosci-
ence), mCD4 (RM4-5; eBioscience), mCD8a (53-6.7; 
eBioscience), mCD25 (PC61.5; eBioscience), mCD44 
(IM7; eBioscience), mGranzyme B (NGZB; eBioscience), 
mFoxP3 (FJK- 16s; eBioscience), mF4/80 (BM8; eBiosci-
ence), mCD11c (N418; eBioscience), mCD11b (M1/70; 
eBioscience), mLy- 6G (1A8- Ly6G; eBioscience). All 
samples were run on LSRFortessa (BD biosciences) and 
analyzed with FlowJo software (Tree Star).
Enzyme-linked immunosorbent assay
Measurement of interferon (IFN)-γ and interleukin (IL)- 
12p40 in the serum of transgenic mice was performed 
using ELISA kit (Biolegend, San Diego, California, USA). 
Optical density reading at 450 nm were measured using 
a VERSAmax microplate reader (Molecular Devices). 
The cytokine concentration was normalized by protein 
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concentration which has been measured by BCA kit 
(Thermo Fisher, USA).
Multiplexed immunohistochemistry
Immunohistochemical protocols were performed using 
4 mm thick sections, mCD8 antibody (Cell Signaling) as 
primary antibody. All slides were stained by Bond RX fully 
automated staining device (LEICA), scanned by Vectra 
Polaris (Perkin Elmer), and analyzed by Phenochart and 
InForm (Perkin Elmer) according to the manufacturer’s 
protocol. The anti- mPD- L1, anti- Pan- CK, anti- mCD8, 
anti- mFoxp3, anti- mPD-1 and anti- mGranzyme B anti-
bodies were applied for multiplex immunohistochem-
istry. The InForm software was used for analysis tissue and 
cell segmentation. The individual cells including target 
expression were integrated and converted by R (V.3.6.1). 
The converted matrix files were analyzed for deconvo-
luted results by FlowJo software (V.10.6.2).
RNA sequencing and TCR repertoire analysis
Total RNA was extracted from vehicle and ceritinib- 
resistant tumors using TRIzol RNA isolation reagents 
(Life Technologies, Carlsbad, California, USA). RNA 
integrity was analyzed using a bioanalyzer with the Agilent 
RNA 6000 pico kit (Agilent Technologies, Santa Clara, 
California, USA). The extracted total RNA was processed 
to prepare the mRNA- sequencing library using the 
TruSeq stranded mRNA LT sample preparation kit (Illu-
mina, San Diego, California, USA) according to manu-
facturer’s instructions. All samples were sequenced on an 
Illumina HiSeq2500 sequencer using paired- end 100 bp 
reads. The raw image data were transformed by base- 
calling into sequence data and stored in FASTQ format. 
Paired- end reads of the five independent samples were 
trimmed for both PCR and sequencing adapters with 
Cutadapt (http:// cutadapt. readthedocs. io/ en/ stable/; 
V.1.16). Trimmed reads were aligned to the GRCm38 
mouse reference genome using STAR (V.2.6.0a)20 and 
gene- level read counts were generated using feature 
Counts function from the Subread package (V.1.6.2).21 
The presence of significant differential expression was 
determined by DESeq2 package (V.1.26)22 at the gene 
level. All gene sets in V.7.0 of the Molecular Signatures 
Database were analyzed by V.4.0.3 of gene set enrichment 
analysis (GSEA) and corrected for multiple hypothesis 
testing. The p value threshold was set at 0.05.23 Heatmaps 
of differentially expressing genes was generated using the 
prism (V.8.0). To analyze TCR repertoire, the high- depth 
RNA sequencing was performed. TCR sequences were 
extracted by V.3.0 of MiXCR, and analyzed by TcR pack-
ages (V.2.2.4.1).
Whole exome sequencing
SureSelect (target enrichment system) was applied for 
exome capture sequencing process. The hybridized 
genome sample with biotinylated RNA library ‘BAITS’ 
was mixed with streptavidin- coated magnetic beads. The 
bead captured genomes were washed and RNA digest. 
The collected genome particles were analyzed by next- 
generation sequencing. The FASTQ file was generated 
by RTA V.1.12.4/CASAVA V.1.8.2. The FASTQ files were 
aligned on mm10 genome reference, then generated to 
BAM file. Extract mappable read, on- target reads, SNP 
and Indels were generated by analysis pipe lines. The 
read mapping was performed by BWA. The mark dupli-
cates filter (Picard), Indel realignment (GATK) and base 
recalibration were performed for variant calling. The 
GATK was used for variant calling, variant filtering.
Masson’s trichrome and reticulin staining of liver tissue
In sections stained with Masson’s trichrome stain, 
collagen staining was separately quantitated in the liver. 
Gomori’s silver impregnation methods for reticulin fibers 
were carried out on formalin- fixed, paraffin- embedded 
sections mounted on glass slides. Three slides per group 
were analyzed. The proportional area of blue stain in each 
section was recorded by using analytical imaging software, 
and the average from five fields was calculated to yield a 
relative value of collagen staining per field.
Statistical analysis
Survival analyses were estimated using Kaplan- Meier 
method and associated 95% CIs. All statistical analyses and 
graphs were performed using SPSS V.23.0 software (IBM, 
Chicago, Illinois, USA) and GraphPad Prism (V.8.0).
RESULTS
Mouse clinical trial shows anti-PD-1 treatment is ineffective 
in ALK-positive lung cancer
We designed a three- arm trial consisting of anti- PD-1 
and ceritinib to evaluate the efficacy and toxicity of each 
treatment. The schematic design of this study is shown 
in figure 1A. Mice in each arm were allocated to the 
following treatment arms. arm A: anti- PD-1 followed by 
ceritinib (n=9), arm B: ceritinib followed by anti- PD-1 
(n=11) and arm C: anti- PD-1 and ceritinib combination 
(n=6). When tumors showed progression in arm A and 
arm B (defined as PD1), second- line therapy was desig-
nated as the following: anti- PD-1 was switched to ceritinib 
and was continued until progression (PD2), ceritinib was 
switched to anti- PD-1 and was continued until progression 
(PD2). During the drug treatment, MRI was performed 
every week to measure tumor size and objective response 
was determined as described in online supplementary 
figure 1.
The swimmer’s plot in figure 1B shows the treatment 
duration of three arms. Upfront ceritinib (arm B) or ceri-
tinib and anti- PD-1 combination (arm C) clearly produced 
more durable responses compared with anti- PD-1 alone 
upfront. Representative MRI images of mouse tumors in 
each arm are shown in figure 1C. Next, we analyzed the 
survival outcome of each treatment in terms of PFS and 
OS (figure 1D). The median PFS1 was 13, 132 and 129 
days for arms A, B and C, respectively. As expected, arm B 
and arm C showed significantly prolonged PFS compared 
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Figure 1 Mouse clinical trial reveals that antiprogrammed death cell protein-1 (PD-1) therapy is ineffective in treatment- naïve 
ALK- positive lung cancer. (A) Schematic diagram showing the three treatment arms. Arm A consists of anti- PD-1 followed 
by ceritinib (n=9), arm B consists of ceritinib followed by anti- PD-1 (n=11) and arm C consists of anti- PD-1 and ceritinib 
combination (n=6). PFS1 is defined as the time duration from drug treatment until first progression. PFS2 is defined as the time 
duration from second drug treatment until second progression. (B) Swimmer’s plot of treatment duration. The three arms of 
treatments are indicated as arm A, arm B and arm C, and the schedule of ceritinib, anti- PD-1 and micro- MRI is depicted below 
the X- axis. Lines of treatment and time points of complete response (CR), partial response (PR) and progressive disease (PD) 
was marked by colors and symbols (red=anti- PD-1, blue=ceritinib, green=anti- PD-1 plus ceritinib, white circle=CR, yellow 
circle=PR, black circle=PD and black arrow=ongoing). (C) Representative coronal T2- weighted MRI images are shown. A mouse 
treated with anti- PD-1 alone showing disease progression (arm A), a mouse treated with ceritinib showing initial response then 
progression after drug resistance (arm B) and a mouse treated with ceritinib and anti- PD-1 combination showed initial response 
then progression after drug resistance (arm C). (D) Progression- free survival (PFS) as determined by Kaplan- Meier curves is 
shown for arm A, arm B and arm C. PFS1, PFS2 and PFS1+2 were compared between individual arms by log- ranked analysis. 
The median survival, CI and statistical significance are demonstrated (two- way analysis of variance, p value: ns, non- significant, 
***p<0.001 and ****p<0.0001).
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with arm A. The PFS1 of arm B and arm C were not signifi-
cantly different, suggesting that combination treatment 
did not prolong PFS in the frontline. The median PFS2 
was 99 days for arm A and 7 days for arm B, suggesting 
that anti- PD-1 treatment after ceritinib resistance was not 
effective. The median PFS1+PFS2 was 112, 139 and 129 
days, respectively, confirming that upfront ceritinib was 
the most effective treatment regimen while combination 
of ceritinib and anti- PD-1 did not add any improvement 
in terms of PFS. These data were in concordance with 
the data from clinical trials summarized previously.10–12 
In addition, we also observed significant hepatotoxicity 
resulting from ceritinib and anti- PD-1 combination treat-
ment, characterized by fibrosis and infiltration of lymph-
oplasmacytic cells (online supplementary figure 2A‒D). 
There was also a significant reduction in body weight after 
day 20 in the combination- treated group compared with 
ceritinib group (online supplementary figure 2E). Next, 
we questioned whether combination treatment after 
failure on sequential treatment could overcome resis-
tance to either sequential treatment (online supplemen-
tary figure 3). Anti- PD-1 was added on after progressing 
on ceritinib in arm A (n=5), ceritinib or anti- PD-1 was 
rechallenged in mice progressing on arm B and PFS3 was 
compared between these groups. There was no signifi-
cant difference between PFS3 among three groups, and 
all regimens were not efficacious. Still, partial responses 
were observed in all mice which may have resulted from 
remaining ALK- dependent clones reactive to TKI. Alto-
gether, anti- PD-1 treatment was ineffective in ALK- positive 
lung cancer, either as a single agent, or in combination 
with ALK TKI in delaying lung cancer progression.
Dynamic changes in immune cells and cytokines are observed 
following treatment
To further investigate immunodynamics following treat-
ment, we examined changes in the tumor immune micro-
environment by performing flow cytometry of tumors 
and bronchoalveolar lavage (BAL) fluid. We compared 
three subsets of immune cells (T lymphocytes, antigen- 
presenting cells, myeloid- derived suppressor cells 
(MDSCs)) at baseline, and at the time of progression. 
Gating strategies are described in online supplementary 
figures 4 and 5. Overall, there were no notable changes 
among T lymphocytes, except regulatory T (Treg) cells 
(CD3+CD4+CD25+Foxp3+), which showed a significant 
increase after ceritinib resistance and after ceritinib 
followed by anti- PD-1 in arm B. Of note, granzyme B 
production did not alter, implying lack of cytolytic function 
by CD8+ T cells24 (figure 2A). Among antigen- presenting 
cells, macrophages (F4/80+) and dendritic cells (CD11c+/
F4/80−) increased after anti- PD-1 or ceritinib or combi-
nation treatment (figure 2B). Among MDSCs, monocytic 
MDSCs (CD11b+Ly- 6G−) were increased after anti- PD-1, 
and granulocytic MDSCs (CD11b+Ly- 6G+) were increased 
after ceritinib followed by anti- PD-1 (figure 2C). We 
also noted changes in the cytokines obtained from BAL 
fluid (figure 2D), that IL- 12p40 which upregulates IFN-γ 
secretion,25 was increased after anti- PD-1 followed by 
ceritinib. IFN-γ was increased after anti- PD-1 and ceri-
tinib, which may result from immunogenic cell deaths 
following treatment26 or may be produced by increased 
antigen- presenting cells.27 Altogether, we presume that 
upregulation of IFN-γ following treatment may have stim-
ulated development and recruitment of Tregs, MDSCs, 
tumor- associated macrophages and dendritic cells in 
tumor.27 28 To better compare the tumor immune micro-
environment before and after treatment, we focused on 
pretreatment, postceritinib resistance, postcombination 
resistance samples for further experiments involving 
multispectral imaging, whole exome sequencing and 
RNA sequencing.
Comparison of tumor immune microenvironment before 
and after ceritinib or combination treatment reveals lack of 
immunogenicity
Next, we compared tumor immune microenviron-
ment in the treatment- naïve and ceritinib- resistant 
and combination- resistant tumors to examine changes 
in the immune microenvironment. On multispectral 
imaging, treatment- naïve tumors showed paucity of 
tumor infiltrating T cells, characterizing the so- called 
‘cold tumors’.29 Ceritinib- resistant and combination- 
resistant tumors showed dramatically increased PD- L1 
staining cells, while changes in the expression of CD8, 
FoxP3, granzyme B and PD-1 staining cells were modest. 
A representative image is seen in figure 3. For quanti-
fication, we further examined the expression of CD8, 
Foxp3, PD-1, granzyme B, PD- L1- positive cells by decon-
volution analysis obtained from multispectral imaging 
(figure 4A). When we compared expression levels of 
PD- L1, PD-1 and Foxp3 at pretreatment, postceritinib 
resistance and postcombination resistance, PD- L1 and 
Foxp3 were again dramatically increased after ceritinib 
and combination resistance, but not PD-1 expression 
(figure 4B). Phenotypic analyses revealed that PD- L1- 
expressing cancer cells were increased after ceritinib and 
combination treatment, while there were no significant 
changes in PD-1- expressing CD8+ T cells and granzyme 
B- expressing CD8+ T cells, suggesting that these CD8+ T 
cells may not be cytotoxic (figure 4C). Segmentation of 
tumors from tumor nest and stroma showed upregulation 
of PD- L1 staining cells both in the tumor nest and stroma 
after ceritinib resistance (figure 4D). A close up image 
of ceritinib- resistant tumor showed staining of CD8+ 
T cells surrounded by PD- L1- staining cells and Foxp3- 
positive Treg cells (figure 4E,F). Altogether, we assumed 
that resistance to ceritinib or combination treatment may 
lead to increased number of CD8+ T cells which are just 
bystanders.30
We have previously observed that ALK- positive tumors 
are resistant to anti- PD-1 treatment either upfront 
or after ceritinib resistance (figure 1). Treatment- 
naïve ALK- positive tumors were also devoid of CD8+ 
T cells (figure 3), suggesting that these tumors are 
non- immunogenic. To further explore immunological 
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landscape of primary resistance to ICIs, we performed 
whole exome sequencing of treatment- naïve tumors and 
ceritinib- resistant tumors. ALK kinase domain of the ALK 
gene was directly sequenced to identify known resistant 
ALK mutations, but no known ALK mutation was found 
(data not shown). When the TMB, as calculated by muta-
tions per mega- base, was compared, there was no signif-
icant difference between the two groups (figure 5A). 
As tumor antigen- specific CD8+ T cells expand clonally 
during immune response, we analyzed T- cell receptor 
(TCR) sequences to identify clonally expanded cells as 
an indicator of tumor specificity. We also compared the 
changes in CDR3 length which could affect TRB (which 
encodes TCRβ) sequences. TRB analysis revealed that 
relative usage frequency of TRBV and TRBJ gene was 
not significantly different between pretreatment and 
postceritinib tumor (online supplementary figure 6). We 
noted that variations in CDR3 length did not affect TCR 
repertoire (figure 5B, online supplementary figure 7). 
In addition, there was no significant change in clonality 
between pretreatment and postceritinib tumor (online 
supplementary figure 8). Principal component analyses 
of treatment- naïve and ceritinib- resistant tumors showed 
a large variation between the two groups (figure 5C). 
Figure 2 Immunodynamics are shown in tumor microenvironment after progression of sequential and combination treatments. 
(A) Tumor infiltrating T- cell subsets were measured by anti- CD3, anti- CD4, anti- CD8, anti- Foxp3, antiprogrammed death cell 
protein-1 (PD-1) and antigranzyme B antibodies in pretreatment and postprogression groups. Total T- cell population was 
identified by CD3+ cells from total lymphocyte gate. Helper T- cell and cytotoxic T- cell populations were CD3+CD4+ cells and 
CD3+CD8+ cells, respectively. To identify regulatory T cell, CD25+Foxp3+ cells were measured from helper T cell population. 
The granzyme B expressing cytotoxic T cells were measured from CD3+CD8+ cells. The number of mice involved in each time 
point is marked at the top. (B) Antigen- presenting cells, macrophage and dendritic cells were identified by F4/80 and CD11c 
expression. The F4/80, a pan- macrophage marker was used to identify macrophage population. The dendritic cell population 
was measured by CD11c+ cells in F4/80− gate. (C) The G- myeloid- derived suppressor cell (MDSC) and M- MDSC were 
measured by CD11b+Ly- 6G+ and CD11b+Ly- 6G− cells, respectively. (D) Interleukin (IL)- 12p40 and interferon (IFN)-γ expression 
was measured in bronchoalveolar lavage (BAL) fluid. All data was analyzed with two- way analysis of variance and their 
significance is marked with symbolic digits (p value: ns, non- significant, *p<0.05).
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These findings suggest a lack of antigen specificity among 
CD8+ T cells in ceritinib resistance.
Furthermore, RNA sequencing analysis of pretreatment 
and ceritinib- resistant tumor was performed to gain a 
more in- depth understanding of the immune phenotype. 
Volcano plot comparisons between the pretreatment and 
postceritinib tumor identified 197 transcripts (145 genes 
up, 52 genes down) that were differentially expressed 
between the two cell populations (figure 6A). Network 
analysis showed that upregulated genes showed a higher 
clustering coefficient than downregulated genes (online 
supplementary figure 9). Among upregulated gene set, 
genes that respond to IFN-γ, as well as negative regulation 
of immune system process inflammatory response and 
monocyte chemotaxis were noted by GO term analysis 
(figure 6B,C). GSEA also revealed that gene transcripts 
associated with Treg cell differentiation (GO), classically 
activated macrophage versus type 2 activated macrophage 
up (GSE4811), and IL-4 versus IL-4 and dexamethasone- 
treated macrophage up (GSE7568) were significantly 
enriched in ceritinib- resistant tumors (figure 6D). 
Dexamethasone and IL-4- treated macrophages help 
Figure 3 Expression of immune cells and immune activation markers in tumor microenvironment after progression on 
ceritinib and combination treatment. To analyze expression of immune population and activation markers in tumor, multiplex 
immunohistochemistry was performed in three groups: pretreatment (n=3), postceritinib resistance (n=3) and postcombination 
resistance (n=3). The representative images of tumor infiltrating immune cells and activation markers were identified by the 
following antibodies; Pan- CK (cancer marker), CD8 (cytotoxic T- cell marker), Foxp3 (regulatory T- cell marker), granzyme B and 
programmed death cell protein-1 (PD-1) (T- cell activation and inhibitory markers). The positive markers displayed brownish 
color, and the blue color was used for nucleus localization. The mixed image was merged and each image was represented in 
different index colors (cyan=pan CK, green=CD8, magenta=Foxp3, yellow=programmed death- ligand 1 (PD- L1), white=PD-1 
and blue=DAPI).
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Figure 4 Deconvolution analysis of multispectral imaging for understanding tumor microenvironment after progression on 
ceritinib and combination treatment. Multispectral image analysis was performed by InForm software. The individual cell 
information was extracted from tumor images (n=3 per group). The information of cells was represented using intensity of six 
markers (Pan- CK, CD8, Foxp3, granzyme B, programmed cell death ligand 1 (PD- L1) and programmed cell death 1 (PD-1)). 
All cell data were integrated as a large- scale matrix (26,680 cells) to non- biased clustering. The t- Stochastic Nearest Neighbor 
(tSNE) analysis was performed for dimensional reduction with parameters (iteration=1000, learning rate=18,244, gradient 
algorithm=fit SNE). (A) The expression of CD8, Foxp3, PD-1, granzyme B and PD- L1 markers were presented as a normalized 
color gradient expression. The key color was demonstrated at right from tSNE plot. (B) The PD- L1, PD-1 and Foxp3 expression 
and cell population were individually displayed by groups. (C) Histogram of immune checkpoints and granzyme B expressions 
were compared with cancer cell and immune cells (gray=pretreatment, blue=postceritinib resistance, green=postcombination 
resistance). (D) PD- L1 expression of cancer and non- cancer cell populations at both pretreatment and postceritinib- resistant 
tumor is shown. (E) A CD8+ T cell is surrounded by PD- L1+ cells and regulatory T cells in postceritinib resistance (white 
arrow=CD8+ T cell, T=tumor nest, ST=stroma). (F) Enlarged image of white box at (E). Individual arrows indicate CD8+ T cell and 
regulatory T cell. The dot- line marked the location of CD8+ T cell. CD8+ T cell did not express PD-1 on the surface and was 
surrounded by regulatory T cells (Foxp3+) and PD- L1- expressing cells.
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conversion of M2 macrophage to M2c subtype, which 
plays a role of strong immune suppression and decreased 
antigen presentation.31 Of note, among the core enrich-
ment genes described in figure 6E, genes involved in Treg 
cell function such as suppressor of cytokine signaling 
(SOCS1)32 showed a significant enrichment in ceritinib 
resistance. These data are concordant with the previous 
data in figures 2–4 that Treg cells are increased after ceri-
tinib resistance.
DISCUSSION
ALK- rearranged lung cancer is an important molecular 
subtype in Asia, considering that approximately 10% 
of patients with lung adenocarcinoma in Asian never- 
smokers carry the activating gene.33 In this regard, the 
lack of benefit of anti- PD-1/PD- L1 therapy to ALK- 
rearranged lung cancer treatment raises concern.11 In 
this study, we confirmed that anti- PD-1 did not have anti-
tumor efficacy in EML4- ALK tumors, either alone or in 
combination with ceritinib. Combination treatment of 
ceritinib and anti- PD-1 resulted in a severe hepatotoxicity, 
recapitulating the results in previous clinical trials.12 16 We 
observed notable immunodynamics following treatment 
with anti- PD-1, ceritinib or ceritinib and anti- PD-1 combi-
nation. Deep analysis of the immune infiltrates of the 
tumors revealed that despite the upregulation of PD- L1 
in cancer cells, PD-1 and granzyme B- expressing CD8+ T 
cells did not increase, suggesting that these T cells may 
not be functional and the efficacy of anti- PD-1 may be 
limited.
It is known that T- cell response to immunotherapy 
derives from a distinct repertoire of tumor- specific T cell 
clones, and robust response to ICIs have been seen in 
tumors with a high TMB.34 A previous study reported that 
ALK- positive lung cancer is characterized by low TMB 
compared with other genotypes, with the median TMB 
of 2.8 mutations per mega- base,17 suggesting that ALK- 
positive tumors may not have enough tumor neoantigens 
that are recognized by the TCR. Given the low TMB, we 
also looked at whether TMB increased after ceritinib 
resistance, but there was no significant change in TMB. 
Furthermore, no significant change in T cell clonality was 
observed after ceritinib resistance. These data all suggest 
that primary resistance mechanism to ICIs in both 
treatment- naïve and TKI- resistant ALK- positive tumors 
arise from lack of tumor neoantigens that are recognized 
by the TCR.
For PD-1/PD- L1 inhibitor to work in tumor, we need 
generation of tumor reactive T cells, activation of effector 
T- cell function and formation of effector memory T 
cells.35 If any of these steps does not function, tumor 
microenvironment may become inhospitable which may 
preclude proper T- cell function, thereby limiting the effi-
cacy of anti- PD-1. PD-1/PD- L1- independent mechanisms 
of immune escape may also occur, including activation 
of alternate immune checkpoints or co- inhibitory recep-
tors, immune suppressive cytokines, immune inhibitory 
metabolites and immune suppressive cells.36 In our study, 
we noted that Tregs, as characterized by the expression of 
the transcription factor Foxp3, were increased after ceri-
tinib resistance in the tumor. This finding is supported 
by the upregulation of gene expressions related to Treg 
cell differentiation on RNA sequencing after ceritinib 
resistance. Tregs are important immune suppressor cells 
that play a suppressive function in antitumor immunity, 
and infiltration of Tregs into tumor tissues may evoke 
suppression of tumor- specific effector T cells.37 The 
increased Treg cell population might be related to the 
Figure 5 Tumor mutation burden and T- cell receptor 
(TCR) repertoire of pretreatment and postceritinib- resistant 
tumor. (A) Tumor mutation burden (TMB) was measured by 
whole exome sequencing. (P value: NS, non- significant). 
(B) CDR3 length of TCR- beta were analyzed by MixCR and 
TcR analysis packages. The black arrow represents the top 
frequency of CDR3 length. (C) The TCR- beta V and J usages 
were analyzed by principal component analysis (PCA) with 
pretreatment and postceritinib treatment groups. The major 
principal components 1 and 2 were used as PC1 (X- axis) and 
PC2 (Y- axis) in the PCA plot.
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Figure 6 Differentially expressed genes (DEGs) and gene set enrichment analysis (GSEA) between progression of ceritinib 
and pretreatment groups. (A) A total of 24 052 genes are presented in Volcano plots to compare differentially expressed genes 
in postceritinib resistance and pretreatment tumors. DESeq2 package was used for folds of gene expression and statistical 
analysis (folds ≧|2|, p<0.01). The individual gene expression and p values were displayed as colored dots (gray=no- significant 
and no- folds changes, green=folds >|2|, blue ≤0.01, red=folds ≧|2| and p<0.01). Lower expression of 145 genes and higher 
expression of 52 genes were identified in postceritinib resistance tumor. (B) The selected DEGs were analyzed by the gene set 
enrichment with higher expressing 52 genes and lower expressing 145 genes. GO pathway was applied to analyze the meaning 
of previous results. The presented gene sets were significantly enriched gene sets in GO pathway (FDR >0.05). The indicated 
gene sets were highly related to previous results (red square dots=high expressed genes, blue square dots=low expressed 
genes). (C) The heatmaps were presented to show core enrichment genes of previously related gene sets; IFN-γ, negative 
regulation of immune system process and inflammatory response. The gradient key color presents the expression of individual 
genes (Z- score normalized). (D) GSEA with MSigdb.v7.0. (12,999 gene sets). Among the significant gene sets, regulatory T cell 
differentiation (GO), classically activated macrophage versus type 2 activated macrophage up (GSE4811), and IL-4 versus IL-4 
and dexamethasone- treated macrophage up (GSE7568) were demonstrated with normalized enrichment score (NES)and p 
value. (E) The heatmaps were presented to show core enrichment genes.
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SOCS1 expression. SOCS1 is necessary for the suppressor 
function of Treg cells, and plays important roles in Treg 
cell integrity and function by maintaining Foxp3 expres-
sion.32 The increased intensity of Foxp3 on multispectral 
imaging, increased Treg cell population and suppressed 
T- cell activity all correlate with each other. Whether or 
not Tregs played a major role in counteracting efficacy 
of anti- PD-1 after ceritinib resistance needs to be further 
explored.
We revealed mechanisms of toxicity when combining 
ALK TKI and ICI, showing that increased infiltration 
of lymphoplasmacytic cells in peri- venular areas were 
inducing hepatic damage. Similarly, recent reports 
suggested that sequential ICI and crizotinib is associ-
ated with a significantly increased risk of hepatotox-
icity.26 38 Therefore, we suggest that careful consideration 
and monitoring for hepatotoxicity may be warranted in 
ALK- positive patients receiving combination treatment.
CONCLUSION
We demonstrated that PD-1 inhibitor is not beneficial 
for ALK- rearranged lung tumors and that combination 
of ALK TKI and PD-1 inhibitor do not improve survival 
outcome via EML4- ALK transgenic mice. Dynamic 
changes of the tumor- immune microenvironment in 
response to treatments revealed that ALK- positive NSCLC 
is devoid of tumor recognition and immune- specific 
tumor killing. We believe that this work leads to a deeper 
understanding of tumor biology when incorporating ICIs 
in the treatment of ALK- positive NSCLCs.
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